Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles

Microtubule-targeted agents are commonly used for cancer treatment, though many patients do not benefit. Microtubule-targeted drugs were assumed to elicit anticancer activity via mitotic arrest because they cause cell death following mitotic arrest in cell culture. However, we recently demonstrated that intratumoral paclitaxel concentrations are insufficient to induce mitotic arrest and rather induce chromosomal instability (CIN) via multipolar mitotic spindles. Here, we show in metastatic breast cancer and relevant human cellular models that this mechanism is conserved among clinically useful microtubule poisons. While multipolar divisions typically produce inviable progeny, multipolar spindles can be focused into near-normal bipolar spindles at any stage of mitosis. Using a novel method to quantify the rate of CIN, we demonstrate that cell death positively correlates with net loss of DNA. Spindle focusing decreases CIN and causes resistance to diverse microtubule poisons, which can be counteracted by addition of a drug that increases CIN without affecting spindle polarity. These results demonstrate conserved mechanisms of action and resistance for diverse microtubule-targeted agents. Trial registration: clinicaltrials.gov, NCT03393741.

[1]  Z. Storchová,et al.  Consequences of chromosome gain: A new view on trisomy syndromes. , 2022, American journal of human genetics.

[2]  G. Kops,et al.  Nuclear chromosome locations dictate segregation error frequencies , 2022, Nature.

[3]  B. Weaver,et al.  Chromosome Missegregation as a Modulator of Radiation Sensitivity. , 2022, Seminars in radiation oncology.

[4]  M. Burkard,et al.  Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel , 2021, Science Translational Medicine.

[5]  T. Ried,et al.  Clonal selection of stable aneuploidies in progenitor cells drives high-prevalence tumorigenesis , 2021, Genes & development.

[6]  P. Meraldi,et al.  Forcing dividing cancer cells to die; low‐dose drug combinations to prevent spindle pole clustering , 2021, Apoptosis.

[7]  J. Korbel,et al.  Systems approaches identify the consequences of monosomy in somatic human cells , 2021, Nature Communications.

[8]  A. Roopra,et al.  p53 Is Not Required for High CIN to Induce Tumor Suppression , 2020, Molecular Cancer Research.

[9]  Karen H. Miga,et al.  Human chromosome‐specific aneuploidy is influenced by DNA‐dependent centromeric features , 2019, The EMBO journal.

[10]  A. Amon,et al.  Context is everything: aneuploidy in cancer , 2019, Nature Reviews Genetics.

[11]  H. Funabiki,et al.  The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death , 2019, Cell.

[12]  Christopher D. Laucius,et al.  Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas , 2019, Cell cycle.

[13]  S. McClelland,et al.  Impaired CENP-E Function Renders Large Chromosomes More Vulnerable to Congression Failure , 2019, Biomolecules.

[14]  Z. Storchová,et al.  The diverse consequences of aneuploidy , 2019, Nature Cell Biology.

[15]  I. Huijbers,et al.  Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division , 2018, British Journal of Cancer.

[16]  F. Foijer,et al.  Non-random Mis-segregation of Human Chromosomes , 2018, bioRxiv.

[17]  D. Grieco,et al.  Fighting tubulin-targeting anticancer drug toxicity and resistance. , 2017, Endocrine-related cancer.

[18]  R. Medema,et al.  p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies. , 2017, Cell reports.

[19]  Angelika Amon,et al.  Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. , 2017, Developmental cell.

[20]  D. Beebe,et al.  High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation , 2016, Molecular biology of the cell.

[21]  Jan O. Korbel,et al.  Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth , 2016, Cell reports.

[22]  D. Compton,et al.  Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. , 2016, Cancer discovery.

[23]  Shiv D. Kale,et al.  Selective advantage of trisomic human cells cultured in non-standard conditions , 2016, Scientific Reports.

[24]  Ashley M. Laughney,et al.  Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution. , 2015, Cell Reports.

[25]  R. Medema,et al.  Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  K. Polyak,et al.  Oncogene-like induction of cellular invasion from centrosome amplification , 2014, Nature.

[27]  J. O’Shaughnessy,et al.  Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer , 2014, Breast Cancer Research and Treatment.

[28]  Mark E. Burkard,et al.  Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles , 2014, Science Translational Medicine.

[29]  Eiman Mukhtar,et al.  Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.

[30]  A. Amon,et al.  Aneuploidy: implications for protein homeostasis and disease , 2014, Disease Models & Mechanisms.

[31]  Lauren M. Zasadil,et al.  Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors , 2013, Proceedings of the National Academy of Sciences.

[32]  P. Albers,et al.  Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer , 2013, Investigational New Drugs.

[33]  Jordan Ma,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2012 .

[34]  T. Campbell,et al.  Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. , 2012, Cancer treatment reviews.

[35]  Weimin Bi,et al.  Aneuploidy as a mechanism for stress-induced liver adaptation. , 2012, The Journal of clinical investigation.

[36]  J. Baselga,et al.  Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[37]  R. Schmid,et al.  A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network , 2012, British Journal of Cancer.

[38]  M. Minden,et al.  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia , 2012, Investigational New Drugs.

[39]  A. Tan,et al.  A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors , 2012, Investigational New Drugs.

[40]  E. Heath,et al.  First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer , 2012, Cancer Chemotherapy and Pharmacology.

[41]  A. Fojo,et al.  Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale , 2012, Clinical Cancer Research.

[42]  T. Fojo,et al.  Mitosis is not a key target of microtubule agents in patient tumors , 2011, Nature Reviews Clinical Oncology.

[43]  Christopher D. Cox,et al.  Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. , 2010, Anti-cancer agents in medicinal chemistry.

[44]  D. Compton,et al.  CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore‐microtubule dynamics to promote mitotic progression and fidelity , 2010, The EMBO journal.

[45]  K. Pollok,et al.  Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma , 2010, British journal of haematology.

[46]  H. Kovar AURKA inhibitors: Right in time , 2010, Pediatric blood & cancer.

[47]  Neysa Nevins,et al.  Antitumor activity of an allosteric inhibitor of centromere-associated protein-E , 2010, Proceedings of the National Academy of Sciences.

[48]  Leslie Wilson,et al.  Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. , 2010, Biochemistry.

[49]  J. D. Elliott,et al.  Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. , 2010, ACS medicinal chemistry letters.

[50]  D. Baker,et al.  Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. , 2009, Cancer cell.

[51]  Jeffrey Ecsedy,et al.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. , 2009, Blood.

[52]  R. Medema,et al.  Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells , 2009, Proceedings of the National Academy of Sciences.

[53]  B. Tunquist,et al.  ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. , 2009, Anticancer Research.

[54]  J. Berman,et al.  Acquisition of Aneuploidy Provides Increased Fitness during the Evolution of Antifungal Drug Resistance , 2009, PLoS genetics.

[55]  David A. Smith,et al.  Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Schöffski Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. , 2009, The oncologist.

[57]  M. Dimopoulos,et al.  A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer , 2009, Breast Cancer Research and Treatment.

[58]  Samuel F. Bakhoum,et al.  Genome stability is ensured by temporal control of kinetochore-microtubule dynamics , 2008, Nature Cell Biology.

[59]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[60]  D. Baker,et al.  Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis , 2007, The Journal of cell biology.

[61]  Maitreya J. Dunham,et al.  Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast , 2007, Science.

[62]  J. Sparano,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  E. Perez,et al.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Compton,et al.  The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. , 2007, Molecular biology of the cell.

[65]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[66]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[67]  D. Compton,et al.  Mechanisms of Spindle-Pole Organization Are Influenced by Kinetochore Activity in Mammalian Cells , 2007, Current Biology.

[68]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Marina Bibikova,et al.  Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. , 2005, Molecular biology of the cell.

[70]  D. Green,et al.  Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.

[71]  Helder Maiato,et al.  Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. , 2004, Developmental cell.

[72]  G. Chin,et al.  Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. , 2004, Molecular biology of the cell.

[73]  Geert J P L Kops,et al.  Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[75]  S. Horwitz,et al.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. , 2002, Cancer research.

[76]  W. Gerald,et al.  MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells , 2001, Nature.

[77]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[78]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[79]  B. Schaar,et al.  CENP-E Function at Kinetochores Is Essential for Chromosome Alignment , 1997, The Journal of cell biology.

[80]  P Wadsworth,et al.  Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. , 1997, Molecular biology of the cell.

[81]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[82]  Kevin C. Chu,et al.  Differential Effects of Vinblastine on Polymerization and Dynamics at Opposite Microtubule Ends* , 1996, The Journal of Biological Chemistry.

[83]  E. Eisenhauer,et al.  Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  P. Wadsworth,et al.  Vinblastine suppresses dynamics of individual microtubules in living interphase cells. , 1995, Molecular biology of the cell.

[85]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[86]  W. B. Derry,et al.  Substoichiometric binding of taxol suppresses microtubule dynamics. , 1995, Biochemistry.

[87]  J. Garcia-conde,et al.  Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[89]  S. N. Timasheff,et al.  Colchicine analogues that bind reversibly to tubulin define microtubular requirements for newly synthesized protein secretion in rat lacrimal gland. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[91]  J. Lee,et al.  Effects of nocodazole on structures of calf brain tubulin. , 1980, Biochemistry.

[92]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[93]  B. Bhattacharyya,et al.  Colcemid and colchicine binding to tubulin , 1979, FEBS letters.

[94]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[95]  F. Frankel Organization and energy-dependent growth of microtubules in cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[96]  M. De Brabander,et al.  Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. , 1976, Biochemical and biophysical research communications.

[97]  S. Malawista,et al.  Microtubule Crystals: A New Biophysical Phenomenon induced by Vinca Alkaloids , 1968, Nature.

[98]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[99]  J. Ward,et al.  Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. , 2007, Cancer research.

[100]  Cristina Montagna,et al.  Aneuploidy acts both oncogenically and as a tumor suppressor. , 2007, Cancer cell.

[101]  M. Jordan,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.

[102]  D. Richel,et al.  Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  P. Giannakakou,et al.  Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)* , 1997, The Journal of Biological Chemistry.

[104]  B. Kopnin,et al.  Comparison of mitostatic effect, cell uptake and tubulin-binding activity on colchicine and colcemid. , 1981, Biochimica et biophysica acta.

[105]  D. Purich,et al.  Taxol induces microtubule assembly at low temperature. , 1981, Cell motility.

[106]  R. Johnson,et al.  Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978, Cancer treatment reports.

[107]  M. Fernández-Gómez,et al.  Colchicine Effect on the Mitotic Spindle: Estimate of Multipolar Anaphase Production , 1974 .